SIG
ALNY icon

Stonegate Investment Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stonegate Investment Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$244K Sell
535
-149
-22% -$60.7K 0.01% 356
2025
Q2 		$223K Buy
+684
New +$189K 0.01% 363

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Stonegate Investment Group's ALNY Position: Q3 2025 in Review

Stonegate Investment Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q3 2025, selling an estimated $60.7K and leaving 535 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #356.

Stonegate Investment Group first reported a position in ALNY in Q2 2025 and has held it in 2 quarters since. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Stonegate Investment Group held 535 shares of Alnylam Pharmaceuticals worth $244K as of Q3 2025.
  • Stonegate Investment Group sold 149 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $60.7K.
  • Alnylam Pharmaceuticals made up 0.01% of Stonegate Investment Group's portfolio in Q3 2025, its #356 holding.
  • Stonegate Investment Group first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Stonegate Investment Group's 13F filing for Q3 2025, filed 3 Nov 2025.